VolitionRx Limited (NYSE American: VNRX) has highlighted a growing body of clinical and scientific evidence supporting its Nu.Q NETs assay as a biomarker for sepsis and other diseases associated with NETosis. The company released an educational video featuring Critical Care Lead and Medical Consultant Dr. Andrew Retter to discuss the implications. Multiple studies have shown that the Nu.Q H3.1 test can distinguish sepsis from non-infectious inflammation, correlate with disease severity, and provide strong prognostic value for outcomes including organ failure and mortality, according to the company.
Most of the supporting research has been peer reviewed and published, with experts noting the consistency of findings across multiple countries and patient populations. Volition believes its low-cost nucleosome quantification technology could help personalize patient care by identifying elevated H3.1 nucleosome levels as a treatable trait in sepsis management and informing future therapeutic strategies.
Sepsis is a life-threatening condition that arises when the body's response to infection causes tissue damage and organ failure. Early and accurate diagnosis is critical, but current methods have limitations. The Nu.Q H3.1 test measures circulating nucleosomes, which are elevated during NETosis—a process where neutrophils release web-like structures called neutrophil extracellular traps (NETs) that can contribute to inflammation and organ damage in sepsis. By quantifying these levels, the test may enable clinicians to identify patients at higher risk of severe outcomes and tailor treatments accordingly.
The growing evidence base includes studies demonstrating that H3.1 nucleosome levels can differentiate sepsis from systemic inflammatory response syndrome (SIRS) of non-infectious origin, a common diagnostic challenge. Additionally, higher levels have been associated with increased severity of organ failure and higher mortality risk. This prognostic capability could assist in triage and resource allocation in intensive care settings.
Volition is a multinational company focused on advancing the science of epigenetics, aiming to save lives through earlier detection and monitoring of diseases. The company is developing and commercializing simple, cost-effective blood tests for a range of conditions, including some cancers and diseases associated with NETosis. For more information, visit the company's website at https://volition.com/.
The full press release can be accessed at https://ibn.fm/2IH3m. This announcement underscores the potential of the Nu.Q NETs test to address an unmet need in sepsis management, where timely and accurate biomarkers are crucial for improving patient outcomes.
